Skip to main content

Advertisement

Table 2 Cell growth characteristics, IC 50 values and mutation status of ovarian cancer cell lines derived either at initial diagnosis (TOV1369, OV2295, TOV3133G, TOV3133D), or relapse after chemotherapy (OV1369(R2), OV2295(R2), TOV2295(R), OV3133(R), OV3133(R2))

From: Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer

   TOV1369 OV1369 (R2) OV2295 OV2295 (R2) TOV2295 (R) TOV3133G TOV3133D OV3133 (R) OV3133 (R2) TOV112D TOV1946
Cell growth characteristic Doubling time (avg ± SD) 2.87 ± 0.03 2.45 ± 0.12 2.90 ± 0.10 2.73 ± 0.12 2.49 ± 0.49 2.70 ± 0.15 2.63 ± 0.11 2.94 ± 0.07 3.23 ± 0.12 1.49 2.2 ± 0.26
  Saturation densisty 1 (x106 cells) (avg ± SD) 2.37 ± 0.19 3.52 ± 0.12 1.52 ± 0.25 1.63 ± 0.12 1.46 ± 0.07 3.11 ± 0.05 3.14 ± 0.12 2.25 ± 0.25 1.34 ± 0.05 10.64 5.66 ± 0.96
  Number of passages to date >100 >100 >100 120 >100 >100 84 >100 >100 >100 >100
Spheroid formation no aggregate semi- compact semi- compact aggregate semi- compact semi- compact no aggregate compact aggregate
Migration times for wound healing (h) >48 >48 >48 >48 >48 >48 >48 >48 >48 N/D 24
Soft agarose (colony count) 1 Efficiency (avg ± SD) >0.1 8.9 ± 5.7 >.0.1 0.2 ± 0.1 0.1 ± 0.1 >0.1 5.0 ± 2.7 >0.1 6.8 ± 3.2 4.7 ± 1.4 4.7 ± 1.9
Subcutaneous injection Number of mice with tumors 0/6 0/5 0/6 0/6 0/6 0/6 0/6 4/6 0/6 3/3 3/3
  Mean time of tumor appearance (days) 2 N/A N/A N/A N/A N/A N/A N/A 55 ± 11 N/A >10 17 ± 4
IC50 3 Carboplatin (μM) (avg ± SD) 5.64 ± 1.29 8.91 ± 5.00 0.05 ± 0.01 0.84 ± 0.25 0.93 ± 0.06 0.75 ± 0.63 1.75 ± 0.88 1.34 ± 0.37 2.65 13.96 4.04 ± 4.19
  Paclitaxel (nM) (avg ± SD) 22.8 ± 10.7 9.1 ± 6.9 5.4 ± 4.7 2.0 ± 1.5 1.9 ± 0.3 3.5 ± 0.9 2.8 ± 0.3 5.5 ± 3.2 1.6 1.9 3.5 ± 1.8
Mutation TP53 c.730 G > T (Gly244Cys) c.730 G > T (Gly244Cys) c.584 T > C (Ile195Thr) c.584 T > C (Ile195Thr) c.584 T > C (Ile195Thr) c.574C > T (Gln192TE) c.574C > T (Gln192TE) c.574C > T (Gln192TE) c.574C > T (Gln192TE) c.524 G > A 4 (Arg175His) c.817C > T 4 (Arg273Cys)
  1. 1Calculated from two independent experiments (in triplicate);
  2. 2Time to tumor appearance is based on the average of the 4 mice for OV3133(R) that developed tumors, with the tumor mass being greater than 200 mm3;
  3. 3Calculated from three independent experiment except for TOV112D and OV3133(R2), which represent triplicate of a single experiment;
  4. 4Mutation for TP53 previously reported in Ouellet et al., 2008 [19].